Literature DB >> 29626742

Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications.

Ashley Elizabeth Muller1, Ronny Bjørnestad2, Thomas Clausen3.   

Abstract

BACKGROUND: Drop-out is a core problem in opioid maintenance treatment (OMT), but patients' reactions to and acceptance of the various OMT medications are insufficiently investigated. In Norway, there has been vocal patient resistance to the newest medication, buprenorphine-naloxone (BNX), and complaints have focused on the side effect profile. There has been no comparison of patient satisfaction and side effects of the three most common OMT medications. AIM: To compare patient satisfaction with OMT and side effects of BNX, buprenorphine monopreparate (BUP), and methadone (MET) as reported by patients.
METHODS: Data were drawn from a national peer-to-peer survey developed by a patient advocacy group. The survey engaged more than 1000 OMT patients, corresponding to one seventh of OMT patients in Norway. The associations between side effects, treatment satisfaction, and patient characteristics were tested in multinomial logistic regressions.
RESULTS: High patient satisfaction with OMT overall was reported despite lower satisfaction with medication itself and widely prevalent side effects. Among each medication group, dissatisfaction with medications or OMT in general along with poor health status increased the relative risk ratio of reporting the heaviest side effect burden. MET users reported the highest side effect burden and BNX users the lightest, but BNX users were more dissatisfied with their medication.
CONCLUSIONS: Side effects are a concern for nearly all OMT patients, and they do not appear to accumulate with age or length of treatment. BNX users' dissatisfaction with their medication is of particular concern, and expectations and preferences of medication may be influencing their dissatisfaction.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Buprenorphine-naloxone; Opioid maintenance treatment; Patient advocacy; Patient satisfaction; Side effects; peer-to-peer

Mesh:

Substances:

Year:  2018        PMID: 29626742     DOI: 10.1016/j.drugalcdep.2018.02.018

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  11 in total

1.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

2.  Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates.

Authors:  Michael D Stein; Micah T Conti; Debra S Herman; Bradley J Anderson; Genie L Bailey; Donnell Van Noppen; Ana M Abrantes
Journal:  Am J Addict       Date:  2019-04-16

3.  Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting.

Authors:  Joao P De Aquino; Christopher Fairgrieve; Sukhpreet Klaire; Gabriela Garcia-Vassallo
Journal:  J Addict Med       Date:  2020 Sep/Oct       Impact factor: 4.647

4.  Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.

Authors:  Pamela Leece; Triti Khorasheh; Kimberly Corace; Carol Strike; Ahmed M Bayoumi; Sheena Taha; Elisabeth Marks; Beata Pach; Keith Ahamad; Erin Grennell; Melissa Holowaty; Heather Manson; Sharon E Straus
Journal:  BMJ Open       Date:  2019-12-15       Impact factor: 2.692

5.  Large and non-specific somatic disease burdens among ageing, long-term opioid maintenance treatment patients.

Authors:  David Medved; Thomas Clausen; Anne Bukten; Ronny Bjørnestad; Ashley Elizabeth Muller
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-11-16

6.  The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting.

Authors:  Lindsay Mackay; Thomas Kerr; Nadia Fairbairn; Cameron Grant; M-J Milloy; Kanna Hayashi
Journal:  Addict Sci Clin Pract       Date:  2021-04-28

7.  How do people who use drugs receiving Opioid Medication Therapy perceive their treatment ? A multicentre study.

Authors:  Morgane Guillou Landreat; Antoine Dany; Gaelle Challet Bouju; Edouard-Jules Laforgue; J Cholet; Juliette Leboucher; Jean Benoit Hardouin; Caroline Victorri Vigneau; Marie Grall Bronnec
Journal:  Harm Reduct J       Date:  2022-03-28

8.  Opioid and Polydrug Use Among Patients in Opioid Maintenance Treatment.

Authors:  Siv-Elin Leirvaag Carlsen; Linn-Heidi Lunde; Torbjørn Torsheim
Journal:  Subst Abuse Rehabil       Date:  2020-01-29

9.  Polluting pharmaceutical atmospheres: Compulsion, resistance, and symbolism of buprenorphine in Norway.

Authors:  Aleksandra Bartoszko
Journal:  Nordisk Alkohol Nark       Date:  2018-12-19

10.  The role of drug treatment and recovery services: an opportunity to address injection initiation assistance in Tijuana, Mexico.

Authors:  Stephanie A Meyers; Claudia Rafful; Sonia Jain; Xiaoying Sun; Britt Skaathun; Andrew Guise; Patricia Gonzalez-Zuñiga; Steffanie A Strathdee; Dan Werb; Maria Luisa Mittal
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.